Epidemic Intelligence Service, CDC, United States; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States.
Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States.
Vaccine. 2018 Feb 28;36(10):1272-1278. doi: 10.1016/j.vaccine.2018.01.045.
There have been inconsistent reports of decreased vaccine effectiveness (VE) against influenza viruses among older adults (aged ≥ 65 years) compared with younger adults in the United States. A direct comparison of VE over multiple seasons is needed to assess the consistency of these observations.
We performed a pooled analysis of VE over 5 seasons among adults aged ≥ 18 years who were systematically enrolled in the U.S. Flu VE Network. Outpatients with medically-attended acute respiratory illness (cough with illness onset ≤ 7 days prior to enrollment) were tested for influenza by reverse transcription polymerase chain reaction. We compared differences in VE and vaccine failures among older adult age group (65-74, ≥75, and ≥ 65 years) to adults aged 18-49 years by influenza type and subtype using interaction terms to test for statistical significance and stratified by prior season vaccination status.
Analysis included 20,022 adults aged ≥ 18 years enrolled during the 2011-12 through 2015-16 influenza seasons; 4,785 (24%) tested positive for influenza. VE among patients aged ≥ 65 years was not significantly lower than VE among patients aged 18-49 years against any subtype with no significant interaction of age and vaccination. VE against A(H3N2) viruses was 14% (95% confidence interval [CI] -14% to 36%) for adults ≥ 65 years and 21% (CI 9-32%) for adults 18-49 years. VE against A(H1N1)pdm09 was 49% (95% CI 22-66%) for adults ≥ 65 years and 48% (95% CI 41-54%) for adults 18-49 years and against B viruses was 62% (95% CI 44-74%) for adults ≥ 65 years and 55% (95% CI 45-63%) for adults 18-49 years. There was no significant interaction of age and vaccination for separate strata of prior vaccination status.
Over 5 seasons, influenza vaccination provided similar levels of protection among older and younger adults, with lower levels of protection against influenza A(H3N2) in all ages.
与美国年轻成年人(年龄≥65 岁)相比,年龄较大的成年人(年龄≥65 岁)接种流感疫苗的有效性(VE)一直存在不一致的报道。需要对多个季节的 VE 进行直接比较,以评估这些观察结果的一致性。
我们对美国流感 VE 网络系统招募的年龄≥18 岁成年人进行了 5 个季节的 VE 汇总分析。患有经医学诊断的急性呼吸道疾病(发病后≤7 天内就诊的咳嗽)的门诊患者通过逆转录聚合酶链反应检测流感。我们通过交互项比较了不同年龄组(65-74 岁、≥75 岁和≥65 岁)与 18-49 岁成年人之间的 VE 和疫苗接种失败率,按流感类型和亚型进行比较,并按前一季节的疫苗接种状态进行分层,以检验统计学意义。
分析纳入了 20022 名年龄≥18 岁的成年人,这些成年人在 2011-12 年至 2015-16 年流感季节中接受了调查;其中 4785 人(24%)检测出流感阳性。≥65 岁患者的 VE 与 18-49 岁患者的 VE 相比,对任何亚型均无显著差异,且年龄和疫苗接种之间没有显著的相互作用。A(H3N2)病毒的 VE 对≥65 岁成年人为 14%(95%置信区间[CI]为-14%至 36%),对 18-49 岁成年人为 21%(CI 为 9%至 32%)。对 A(H1N1)pdm09 的 VE 对≥65 岁成年人为 49%(95% CI 为 22%至 66%),对 18-49 岁成年人为 48%(95% CI 为 41%至 54%);对 B 型病毒的 VE 对≥65 岁成年人为 62%(95% CI 为 44%至 74%),对 18-49 岁成年人为 55%(95% CI 为 45%至 63%)。在之前的疫苗接种状态的单独分层中,年龄和疫苗接种之间没有显著的相互作用。
在 5 个季节中,流感疫苗在老年和年轻成年人中提供了相似水平的保护,所有年龄段的 A(H3N2)流感保护水平较低。